| Objective:To explore the effectiveness and sanfety of bivalirudin in patients with acute myocardial infarction by percutaneous coronary intervention of xinjiang.Methods: Collecting 400 cases of patients,They were randomly divided into bivalirudin group(203 cases),heparin plus tirofiban group(197 cases),The baseline of clinical date were recorded.,Patients were pollowed-up for 30 days and 1 year.Results: 10cases(4.9%)in the bivalirudin group and 22 caces(11.2%)in heparin plus tirofiban group showed 30 days of bleeding events(RR,0.44;95%CI,0.21~0.91;P=0.003).Two major adverse cardiac and cerebrovascular events(a given bivalirudin 3.4%,heparin plus tirofiban 10.1%;P=0.009).Two net adverse clinical events(a given bivalirudin 8.4%,heparin plus tirofiban 21.3%;P<0.001).Acquired thrombocytopenia(0vs0.5;P=0.49),stent thrombosis(1.6%vs3.2%;P=0.33)and the incidence of acute stent thrombosis(1.0%vs0;P=0.5)showed no statistical significance.Within one year,the major adverse cardiac and cerebrovascular events and the net adverse clinical events of patiengts with bivalirudinwere significantly than heparin plus tirofiban group(P<0.05).MACCE(5.9%vs16.2%;P=0.001),NACE(15.3% vs 29.4%;P=0.001).Acquired thrombocytopenia(0vs0.5;P=0.49),and the incidence of late stent thrombosis(0.5%vs3.2%;P=0.07)showed no statistical significance.Conclusion: In emergency PCI treated STEMI patients of xinjiang,compared with heparin combined tirofiban trearment,bivalirudin can decrease the incidence of bleeding events,incidence of major adverse cardiac and cerebrovascular events,This benefit will continue until 1 year after surgery. |
PDF Full Text Request